ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.91) by 19.78 percent. This is a 4.29 percent decrease over losses of $(0.70) per share from the same period last year.
FDA Gives Accelerated Approval To Amgen’s Drug For Small Cell Lung Cancer Patients
FDA approves Amgen's Imdelltra for treating ES-SCLC, based on response rate and DoR in clinical studies. Approval may depend on further trials.
